Please assess the completion status of the following clinical trial:

Trial Title: A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Outpatient (sub-group will have 3 overnight stays at clinic)~* Diagnosis of asthma (NIH 2007) for at least 6 months~* Male or Eligible female (females of child-bearing potential must use acceptable method of birth control)~* A best AM pre-bronchodilator FEV1 of 60% to 85% of predicted normal value at Screening~* Reversibility of disease demonstrated by at least 12% and 200mL increase in FEV1 .~* Subjects must have been prescribed a non-corticosteroid controller at least 3 months preceding Visit 1, and/or a short-acting beta 2 agonist, without the use of inhaled corticosteroids in the 4 weeks prior to Visit 1~* Subjects must be able to replace their current short-acting Beta-2-agonist with albuterol/salbutamol aerosol inhaler for the duration of the study~* Subjects must be judged capable of withholding albuterol/salbutamol for at least 4 hours prior to study visits~Exclusion Criteria:~* History of life threatening asthma~* Severe asthma exacerbation~* Respiratory infection within expected to affect subject's ability to participate~* Concurrent respiratory disease~* Current smoker or smoking history of 10 pack years or more~* Diseases preventing use of anticholinergics~* Other clinically significant, uncontrolled condition or disease which would pose a safety risk to the patient, or confound interpretation of study results~* Drug allergy to any Beta-2-agonist, sympathomimetic drug, intranasal, inhaled or systemic corticosteroid therapy~* Known or suspected sensitivity to the constituents of the Novel DPI (ie lactose)~* History of severe milk protein allergy~* Administration of prescription or over-the-counter medication that would significantly affect the course of asthma, or interact with the study drug~* Any infirmity, disability or disease of a child or family member likely to impair compliance~* Alcohol or substance abuse history~* Viral hepatitis B surface antigen or Hepatitis C antibody~* Known HIV-positive history.~* Affiliation with investigator or site staff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK573719 15.6 mcg (Type: EXPERIMENTAL): GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily
- GSK573719 31.25 mcg (Type: EXPERIMENTAL): GSK573719 (Umeclinidium bromide) 31.25 mcg once-daily
- GSK573719 62.5 mcg (Type: EXPERIMENTAL): GSK573719 (Umeclinidium bromide) 62.5 mcg once-daily
- GSK573719 125 mcg (Type: EXPERIMENTAL): GSK573719 (Umeclinidium bromide) 125 mcg once-daily
- GSK573719 250 mcg (Type: EXPERIMENTAL): GSK573719 (Umeclinidium bromide) 250 mcg once-daily
- GSK573719 15.6 mcg twice-daily (Type: EXPERIMENTAL): GSK573719 (Umeclinidium bromide) 15.6 mcg twice-daily
- GSK573719 31.25 mcg twice daily (Type: EXPERIMENTAL): Gsk573719 (Umeclinidium bromide) 31.25 mcg twice-daily
- Matched Placebo (Type: PLACEBO_COMPARATOR): Matched Placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete